Secarna Pharmaceuticals
Address: Am Klopferspitz 19, Planegg, Martinsried, Bavaria. 82152About Us
Secarna Pharmaceuticals is the leading independent European antisense drug discovery company with multiple best-in-class antisense therapies in various stages of pre-clinical development addressing high unmet medical needs across several therapeutic areas. Founded in 2015, we are proud to have established our discovery and development unit with more than 2,000 square feet of lab and office space at the IZB Martinsried – one of Europe's most vibrant biotechnology clusters.
Sectors
- Collaborations & Partnerships- R&D
- Collaborations & Partnerships-Licensing
- Collaborations & Partnerships-Manufacture
- Proprietary Research & Manufacture
Categories
- Biologics
- Biotechnology
- Drug Discovery Services
- Antisense
- Oligonucleotides
- Clinical Development-Pipeline
- Platform Technology-Drug Discovery
- Bioconjugation
News
Secarna Pharmaceuticals and Curie.Bio Expand Existing Partnership
Martinsried (Munich), Germany, March 3, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the expansion of the existing scientific and strategic collaboration agreement with Curie.Bio announced in May 2025. The expansion includes Secarna’s support in identifying oligonucleotide candidates using its proprietary OligoCreator® platform for research and development projects conducted by Curie.Bio portfolio companies.
Secarna Pharmaceuticals and Curie.Bio Portfolio Company Enter into Research and Option Agreement
Martinsried (Munich), Germany, May 12, 2025 – Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced the signing of a research and option agreement for a scientific and strategic collaboration with one of Curie.Bio’s portfolio companies.
Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover Peptide-conjugated antisense compounds
MARTINSRIED, Germany & OXFORD, England, May 28, 2024--(BUSINESS WIRE)--Secarna Pharmaceuticals GmbH & Co. KG (Secarna), a leading independent European antisense drug discovery and development company, and Orbit Discovery Ltd. (Orbit), a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.
Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies
Dallas and Martinsried, March 20, 2024 - Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com